Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 751.70K | 339.50K | 770.20K | 438.30K | 252.00K |
| Depreciation & Amortization | 6.70K | 11.80K | 13.90K | 12.30K | 12.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 985.40K | 435.20K | 1.03M | 534.60K | 421.90K |
| Operating Income | -985.40K | -435.20K | -1.03M | -534.60K | -421.90K |
| Income Before Tax | -1.09M | -510.40K | -837.30K | -663.30K | -575.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.09M | -510.40K | -837.30K | -663.30K | -575.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.09M | -510.40K | -837.30K | -663.30K | -575.00K |
| EBIT | -985.40K | -435.20K | -1.03M | -534.60K | -421.90K |
| EBITDA | -978.80K | -428.30K | -1.02M | -522.20K | -409.30K |
| EPS Basic | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 55.35M | 54.73M | 54.71M | 49.21M | 46.20M |
| Average Diluted Shares Outstanding | 55.35M | 54.73M | 54.71M | 49.21M | 46.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |